openPR Logo
Press release

Myelodysplastic Syndromes Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Novartis, Syros, Curis, Ryvu, Amgen, Sanofi, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo, Geron, Astex Pharma, Jazz Pharma, Maxinovel, Medac

01-24-2024 03:50 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Myelodysplastic Syndromes Market Gearing Up for Outstanding

As per DelveInsight, the Myelodysplastic Syndromes Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Myelodysplastic Syndromes and the launch of new therapies in the market.

DelveInsight's "Myelodysplastic Syndromes Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myelodysplastic Syndromes Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Myelodysplastic Syndromes therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Myelodysplastic Syndromes treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Myelodysplastic Syndromes: An Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. In Myelodysplastic Syndromes, also known as myelodysplasia, the bone marrow cells do not develop into mature blood cells; instead, these cells stay within the bone marrow in an immature state. There are many subtypes of Myelodysplastic Syndromes; some cases are mild, while others are more severe and carry a high risk of becoming acute myelogenous leukemia (AML).

Myelodysplastic Syndromes is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable. Not all patients require treatment initially, as there is no survival benefit with the treatment of asymptomatic, low-risk patients.

There are many subtypes of Myelodysplastic Syndromes. The subtype is determined using the results of blood and bone marrow tests. Myelodysplastic Syndromes subtype is determined using either the World Health Organization (WHO) classification system or the French-American-British (FAB) classification system, but the WHO classification is more commonly used today.

The main feature of myelodysplastic syndromes (MDS) is that they cause low blood cell counts. Sometimes this is found on blood tests, even before symptoms appear. In other cases, symptoms related to shortages of one or more types of blood cells (cytopenias) are the first signs of Myelodysplastic Syndromes.

Myelodysplastic Syndromes Market Key Facts
• The Myelodysplastic Syndromes market size in the 7MM was estimated to be USD 1,924 million in 2020, which is expected to grow by 2032.
• The United States accounted for the largest market size of Myelodysplastic Syndrome in comparison to the EU5 (Germany, France, Italy, the United Kingdom, and Spain) and Japan. In the United States, the market size of Myelodysplastic Syndrome was USD 1,301.5 million in 2020.
• Among the EU5 countries, Germany had the highest market size with USD 135.2 million in 2020, while Spain had the smallest market size for Myelodysplastic Syndrome with USD 60.2 million in 2020.
• In 2020, Japan accounted for the market size of Myelodysplastic Syndrome with USD 105.8 million.
• In 2020, the incident population of Myelodysplastic Syndrome in the 7MM was 41,586.
• Among the EU-5 countries in 2020, Germany had the highest incident population of Myelodysplastic Syndrome patients with 4,515 cases, followed by France (4,371) and the UK (3,302). In contrast, Spain had the lowest cases (2,010) in 2020.
• Japan accounted for 3,909 incident Myelodysplastic Syndrome cases in 2020.

Get a Detailed Overview of the Evolving Myelodysplastic Syndromes Market Trends @
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myelodysplastic Syndromes Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Myelodysplastic Syndromes therapies in the market. It also provides a detailed assessment of the Myelodysplastic Syndromes market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Myelodysplastic Syndromes drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Myelodysplastic Syndromes Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myelodysplastic Syndromes Epidemiology
The epidemiology section covers detailed insights into the historical, and current Myelodysplastic Syndromes patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Myelodysplastic Syndromes Epidemiology Segmented as -
• Total Incident Population of Myelodysplastic Syndrome in the 7MM [2019-2032]
• Subtype-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019-2032]
• Risk-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019-2032]
• Subtype-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019-2032]
• Age-specific Incident Population of Myelodysplastic Syndrome in the 7MM [2019-2032]

Myelodysplastic Syndromes Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndromes market or expected to be launched during the study period. The analysis covers the market share of Myelodysplastic Syndromes drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Myelodysplastic Syndromes Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Myelodysplastic Syndromes Market @
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Myelodysplastic Syndromes Therapeutics Assessment
Several major pharma and biotech companies are actively engaged in the development of therapies for Myelodysplastic Syndrome. Among these, several have advanced their Myelodysplastic Syndromes drug candidates to the most critical stage of clinical development, Phase III. One such prominent player in this phase is Novartis.

Leading Companies in the Myelodysplastic Syndromes Therapeutics Market Include
Some of the key companies in the Myelodysplastic Syndromes Therapeutics Market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, Bristol-Myers Squibb, Taiho Oncology, Fibrogen, Gilead Sciences, Takeda, Pfizer, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Aprea Therapeutics, and Medac.

Emerging and Marketed Myelodysplastic Syndromes Therapies Covered in the Report Include
• MBG453: Novartis
• CA-4948: Curis
• RVU120: Ryvu Therapeutics
• Roxadustat: Fibrogen
• Venclexta (Venetoclax) + Azacitidine: AbbVie
• Magrolimab ± Azacitidine: Gilead Sciences
• SY-1425 + Azacitidine: Syros pharmaceuticals
• Pevonedistat ± Azacitidine: Takeda
• Glasdegib + Azacitidine: Pfizer
And Many Others

Learn More About the Emerging Therapies and key Companies in the Myelodysplastic Syndromes Therapeutics Market @
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Myelodysplastic Syndromes Competitive Intelligence Analysis
4. Myelodysplastic Syndromes Market Overview at a Glance
5. Myelodysplastic Syndromes Background and Overview
6. Myelodysplastic Syndromes Patient Journey
7. Myelodysplastic Syndromes Epidemiology and Patient Population
8. Myelodysplastic Syndromes Treatment Algorithm, Current Treatment, and Medical Practices
9. Myelodysplastic Syndromes Unmet Needs
10. Key Endpoints of Myelodysplastic Syndromes Treatment
11. Myelodysplastic Syndromes Marketed Products
12. Myelodysplastic Syndromes Emerging Therapies
13. Myelodysplastic Syndromes Seven Major Market Analysis
14. Attribute Analysis
15. Myelodysplastic Syndromes Market Outlook (7 major markets)
16. Myelodysplastic Syndromes Access and Reimbursement Overview
17. KOL Views on the Myelodysplastic Syndromes Market.
18. Myelodysplastic Syndromes Market Drivers
19. Myelodysplastic Syndromes Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Myelodysplastic Syndromes Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | Novartis, Syros, Curis, Ryvu, Amgen, Sanofi, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo, Geron, Astex Pharma, Jazz Pharma, Maxinovel, Medac here

News-ID: 3362016 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Myelodysplastic

Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market? The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness. The myelodysplastic syndrome (MDS)
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Myelodysplastic
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:  The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.